COMP <GO>
GILD vs JNJ // RSI-14 & 200D SMA MOMENTUM
Gilead Sciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GILD 8
— JNJ 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: GILD
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
rsi-technicals
74.3
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 67.90% | +10.90 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 25.50% | -4.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 18.5x | +2.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 2.97% | +1.63 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | 34.70% | -0.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 28.50% | +0.40 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 6.00% | -3.60 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 0.00% | +1.95 | GILD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 5.59 | +0.28 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | GILD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 74.3 | 60.4 | +13.93 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 23.0x | -0.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $662.49B | -$457.14B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | JNJ REV | GILD GROSS % | JNJ GROSS % | GILD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $94.19B | 78.8% | 67.9% | $9.46B | $19.70B |
| FY 2024 | $28.75B | $88.82B | 78.3% | 69.1% | $10.30B | $19.84B |
| FY 2023 | $27.12B | $85.16B | 44.0% | 44.0% | $6.79B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
JNJ // BETA 1.08